Janssen, an international pharmaceutical company, is committed to the discovery and development of medicines for the treatment of some of the world’s most complex diseases, like cancer. Based on this commitment, Janssen’s Taiwan affiliate was a recipient of Common Wealth Magazine’s 2009 Excellence in Corporate Social Responsibility Awards.
In 2019, the Taiwan-Janssen Project focused on research projects geared toward treating lung and colorectal cancer. R&D proposals from a non-profit division and two academic/research divisions were rated as worthy. The non-profit division, represented by Dr. Ping-fu Cheng and his team from the Biomedical Technology and Device Research Laboratories at the Industrial Technology Research Institute (ITRI), were awarded from Janssen a three-year grant of US$500,000, with an equivalent amount to be appropriated by the MOEA. Of the top three applicants from academic/research division, Assistant Prof. Hsing-chen Tsai and her team from National Taiwan University will secure a MOST grant of US$60,000 for developing blood tests to identify epigenetic markers that could act as early signs of cancer. Meanwhile, Prof. Jung-chun Lin and his team from Taipei Medical University will receive a MOST grant of US$40,000 for developing ways to apply intestinal metagenomic sequencing to the development of an in vitro screening platform meant for people most vulnerable to develop colorectal cancer. Janssen will provide both teams with one-on-one R&D guidance for six months.
MOST Deputy Minister Dar-Bin Shieh cites the World Economic Forum’s (WEF) Global Competitiveness Report 2019 that continued to rank Taiwan among global leaders in terms of innovation capability: No. 4 worldwide and No. 1 in the Asia Pacific. Moreover, the WEF rated Taiwan as one of the world’s four “super innovators.” Using its Health Care Index to gauge 89 countries, CEOWORLD Magazine also granted Taiwan the honor of No. 1. Taiwan has attracted the attention of leading global biotech and pharmaceutical companies because it owns the world’s best medical care system, excellent medical technologies, and top-notch R&D professionals. The MOST and MOEA joined forces with Janssen to foster research teams aimed at meeting the needs of the global medical care market by providing incentives to bring technologies to market and creating a process and model for cross-border collaboration to drive innovation.
Department of Academia-Industry Collaboration and Science Park Affairs,
Ministry of Science and Technology (MOST)
Tel : 886-2-2737-7212